4.8 Article

BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer

Journal

CANCER RESEARCH
Volume 68, Issue 6, Pages 1667-1674

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-07-5276

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R01 CA082783-04, R01 CA082783-10, R01 CA082783-07, R01 CA082783-06, P01 CA097403-06A1, R01 CA082783-05, R01 CA082783, CA082783, CA097403, P01 CA097403] Funding Source: Medline

Ask authors/readers for more resources

Screening for tumor suppressor genes in breast cancer revealed multiple truncating mutations of PB1, which encodes the BAF180 subunit of the PBAF chromatin remodeling complex. Mutation was associated with loss of heterozygosity of the wild-type allele. BAF180 complementation of BAF180-mutant tumor cells caused G] arrest that was dependent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Endogenous wild-type BAF180 bound to the p21 promoter and was required for proper p21 expression and G(1) arrest after transforming growth factor-beta and gamma-radiation treatment. BAF180 thus functions on two tumor suppressor signaling pathways as a physiologic mediator of p21 expression. We conclude that BAF180 suppresses tumorigenesis, at least in part, through its ability to regulate p21.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available